QURE

uniQure NV (QURE)

uniQure NV

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:QURE

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/07	21:03	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:QURE	uniQure NV
2024/05/07	20:57	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:QURE	uniQure NV
2024/05/07	20:05	GlobeNewswire Inc.	uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress	NASDAQ:QURE	uniQure NV
2024/03/06	07:14	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:QURE	uniQure NV
2024/03/06	07:10	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:QURE	uniQure NV
2024/03/06	06:58	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:QURE	uniQure NV
2024/03/06	06:54	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:QURE	uniQure NV
2024/02/29	06:33	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:QURE	uniQure NV
2024/02/28	22:29	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:QURE	uniQure NV
2024/02/28	22:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:QURE	uniQure NV
2024/02/28	21:05	GlobeNewswire Inc.	uniQure Announces 2023 Financial Results and Highlights Recent Company Progress	NASDAQ:QURE	uniQure NV
2024/02/27	06:46	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:QURE	uniQure NV
2024/02/27	06:25	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:QURE	uniQure NV
2024/02/14	06:33	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:QURE	uniQure NV
2023/12/19	21:12	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:QURE	uniQure NV
2023/12/19	21:05	GlobeNewswire Inc.	uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease	NASDAQ:QURE	uniQure NV
2023/12/12	09:30	PR Newswire (US)	CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B	NASDAQ:QURE	uniQure NV
2023/12/08	21:05	GlobeNewswire Inc.	uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:QURE	uniQure NV
2023/11/29	21:05	GlobeNewswire Inc.	uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease	NASDAQ:QURE	uniQure NV
2023/11/17	20:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:QURE	uniQure NV
2023/11/07	21:52	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:QURE	uniQure NV
2023/11/07	21:31	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:QURE	uniQure NV
2023/11/07	21:05	GlobeNewswire Inc.	uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress	NASDAQ:QURE	uniQure NV
2023/10/27	23:00	PR Newswire (US)	CSL and uniQure Win 2023 Prix Galien USA Award	NASDAQ:QURE	uniQure NV
2023/10/27	03:38	PR Newswire (Canada)	Santé Canada autorise HEMGENIX® de CSL (étranacogène dézaparvovec) comme première thérapie génique pour l'hémophilie B	NASDAQ:QURE	uniQure NV
2023/10/27	03:14	PR Newswire (Canada)	Health Canada Authorizes CSL's HEMGENIX® (etranacogene dezaparvovec) as First Gene Therapy for Hemophilia B	NASDAQ:QURE	uniQure NV
2023/10/24	20:05	GlobeNewswire Inc.	uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting	NASDAQ:QURE	uniQure NV
2023/10/06	19:33	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:QURE	uniQure NV
2023/10/06	19:32	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:QURE	uniQure NV
2023/10/06	05:32	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:QURE	uniQure NV